Skip to main content
. 2017 Jul 28;10(6):759–768. doi: 10.1093/ckj/sfx087

Fig. 6.

Fig. 6.

ROC analyses for predicting AKI progression or AKI progression with death. (A) The area under the curve (AUC) of renal injury biomarkers [urinary NGAL (uNGAL), urinary IL-18 (uIL-18)] and clinical model, at the time of AKI diagnosis, for predicting AKI progression. (B) The AUCs of renal injury biomarkers (uAGT, uNGAL, uIL-18) and clinical model, at the time of AKI diagnosis, for predicting AKI progression with subsequent death. (C) The performance of combination of renal injury biomarkers for predicting AKI progression. The clinical risk model includes age, gender, hypertension, diabetes, preadmission eGFR, NT-proBNP, serum albumin, hemoglobin, diuretic dosage before AKI, use of spironolactone before AKI, use of RAS inhibitors before AKI and change of serum creatinine from baseline at the time of AKI diagnosis. Figure adapted with permission from Chen et al. [81].